“Charter understands the need to go beyond our customers` expectations in orderto differentiate ourselves from our competitors,” said Phil Bellaria, VicePresident of Customer Loyalty at Charter. By inhibiting these enzymes, which affect the signaling of multiplecytokines (proteins released by cells to communicate with other cells) that areinvolved in a broad spectrum of inflammatory and autoimmune diseases, treatmentwith CP-690,550 may lead to clinically meaningful improvement for patients CP-690,550 was invented at Groton labs. Pfizer Invites Public to View and Listen to WebcastPfizer will webcast a conference call with investment analysts at 1:00 p.m. EDTon Friday, June 12, 2009 to review Phase 2 data for CP-690,550 This webcast isopen to the public. To view and listen to the webcast, visit our web sitehomepage at and click on the “Pfizer Conference Call withAnalysts at EULAR” link in the Investor Presentations tab. Participants areadvised to pre-register in advance of the conference call. You can also listen to the conference call by dialing either (877) 888-4913 inthe United States or (513) 618-5002 outside of the United States The passwordis “EULAR Webcast”.

Pfizer Inc: Working together for a healthier worldFounded in 1849, Pfizer is the world’s premier biopharmaceutical company takingnew approaches to better health. We discover, develop, manufacture and deliverquality, safe and effective prescription medicines to treat and help preventdisease for both people and animals. We also partner with healthcare providers,governments and local communities around the world to expand access to ourmedicines and to provide better quality health care and health system support.At Pfizer, more than 80,000 colleagues in more than 90 countries work every dayto help people stay happier and healthier longer and to reduce the human andeconomic burden of disease worldwide. DISCLOSURE NOTICE: The information contained in this release is as of June 11,2009. Pfizer assumes no obligation to update any forward-looking statementscontained in this release as the result of new information or future events ordevelopments. This release contains forward-looking information about a product indevelopment, CP-690,550, including its potential benefits as a treatment forrheumatoid arthritis, certain other diseases and solid organ transplant, thatinvolves substantial risks and uncertainties.

Such risks and uncertaintiesinclude, among other things, the uncertainties inherent in research anddevelopment; decisions by regulatory authorities regarding whether and when toapprove any drug applications that may be filed for CP-690,550 as well as theirdecisions regarding labeling and other matters that could affect itsavailability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer`s AnnualReport on Form 10-K for the fiscal year ended December 31, 2008 and in itsreports on Form 10-Q and Form 8-K. Pfizer IncMedia:Jack Cox, 212-733-5017orInvestors:Jennifer Davis, 212-733-0717 Pfizer IncCopyright Business Wire 2009. TORONTO, ONTARIO, Jun 11 (MARKET WIRE) — GA Capital Corp.